Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

AVRBullishCorporate Developmentsnews

High materiality8/10

CMS reimbursement boosts PARADIGM progress as Anteris advances US enrollment

Aug 11, 2026, 7:03 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Key near-term catalysts (CMS reimbursement, U.S. recruitment, regulatory clearances) increase visibility and de-risk the PARADIGM path, potentially elevating valuation, though execution risk and burn remain constraints.

AI summary

What happened, with direct paths to the underlying reporting

Anteris reported Q2 2026 results with key milestones for the PARADIGM trial, including CMS reimbursement eligibility and the start of U.S. recruitment. The trial expanded to Denmark and the Netherlands, with regulatory clearances in Canada and France, and governance was strengthened with new directors as DurAVR advances toward commercialization. Near-term focus is site activation and enrollment ahead of potential data readouts amid ongoing cash burn.

CMS reimbursement eligibility for PARADIGM enables U.S. procedure coverage. Supports site enrollment.
First U.S. patient enrolled and treated in May 2026.
PARADIGM expansion includes U.S., Denmark, Netherlands; Canada and France regulatory clearances.
Board additions Susan Knight and Stephen Denaro enhance governance.
New York Valves 2026 showcased DurAVR progress; symposium and live case.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.